Ulmer’s Life Sciences Industry Group regularly assists national and global corporations with their most urgent legal issues, from pressing transactional matters to drug patenting to high-stakes litigation. Our team advises life sciences clients ranging from biotechnology, pharmaceutical, and medical device companies at all stages of growth on a variety of issues, including regulatory matters, corporate transactions, and the management of IP portfolios.
Clients regularly turn to Ulmer for our nationally recognized practice defending pharmaceutical, medical device, and dietary supplement companies and others in class action litigation, federal multidistrict litigation, and state court mass tort litigation. We have represented clients in high-profile product liability litigation involving, for instance, pain medications, hormone replacement therapies, ADHD medications, gastrointestinal medications, antidepressants, contraceptives, pelvic mesh, and weight-loss medications and supplements. We frequently serve as national counsel in such large-scale litigation efforts. We also assist clients with a wide range of risk management matters addressing regulatory, manufacturing, product liability, supply chain, insurance, product extension, and acquisition/sale issues.
Clients also rely on Ulmer because we understand the business of life sciences companies and the changing regulatory and competitive demands they face. Our team works seamlessly to handle a wide range of transactional matters for our clients, including initial entity formation, corporate governance, mergers and acquisitions, licensing, venture capital, and other debt and equity financings. We strive to provide creative, innovative, and effective legal strategies as we help our dynamic clients explore new alliances, ventures, and collaborations.
Our team members routinely handle novel issues that are shaping the legal landscape in which pharmaceutical companies, medical device makers, and other clients operate. To that task, we bring our legal experience, along with first-hand industry knowledge. We also aim to introduce our clients to prospective investors and partners through our vast connections and strategic programs and events. Our team members have advanced degrees and industry experience in pharmacology, chemistry, biochemistry, medical technology, and engineering. Our team members also have experience with human clinical trials and have published in peer-reviewed scientific journals.
March 11, 2020 – As coronavirus paralyzes the world with fear, bioscience enterprise The Gilla Company has developed and independently tested a product shown to be at least 99.9% effective in killing the deadly virus. The product, Gilla (pronounced “jilä”), received EPA registration last year as a sanitizer and disinfectant...
March 11, 2020